WWOX is a gene that spans an extremely large chromosomal region. It is derived from within chromosomal band 16q23.2 which is a region with frequent deletions and other alterations in a variety of different cancers. This chromosomal band also contains the FRA16D common fragile site (CFS). CFSs are chromosomal regions found in all individuals which are highly unstable. WWOX has also been demonstrated to function as a tumor suppressor that is involved in the development of many cancers. Two other highly unstable CFSs, FRA3B (3p14.2) and FRA6E (6q26), also span extremely large genes, FHIT and PARK2, respectively, and these two genes are also found to be important tumor suppressors. There are a number of interesting similarities between these three large CFS genes. In spite of the fact that they are derived from some of the most unstable chromosomal regions in the genome, they are found to be highly evolutionarily conserved and the chromosomal region spanning the mouse homologs of both WWOX and FHIT are also CFSs in mice. Many of the other CFSs also span extremely large genes and many of these are very attractive tumor suppressor candidates. WWOX is therefore a member of a very interesting family of very large CFS genes.
PaigeAJTaylorKJStewartASgourosJGGabraHSellarGCSmythJFPorteousDJWatsonJE. A 700-kb physical map of a region of 16q23.2 homozygously deleted in multiple cancers and spanning the common fragile site FRA16D. Cancer Res2000; 60: 1690–7.
2.
BergsagelPLKuehlWM. Chromosome translocations in multiple myeloma. Oncogene2001; 20: 5611–22.
3.
BednarekAKLaflinKJDanielRLLiaoQHawkinsKAAldazCM. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res2000; 60: 2140–5.
4.
Ludes-MeyersJHBednarekAKPopescuNCBedfordMAldazCM. WWOX, the common chromosomal fragile site, FRA16D, cancer gene. Cytogenet Genome Res2003; 100: 101–10.
5.
SmithDIZhuYMcAvoySKuhnR. Common fragile sites, extremely large genes, neural development and cancer. Cancer Lett2006; 232: 48–57.
6.
GloverTWBergerCCoyleJEchoB. DNA polymerase alpha inhibition by aphidicolin induces gaps and breaks at common fragile sites in human chromosomes. Hum Genet1984; 67: 136–42.
7.
SutherlandGRRichardsRI. The molecular basis of fragile sites in human chromosomes. Curr Opin Genet Dev1995; 5: 323–7.
8.
RiedKFinnisMHobsonLMangelsdorfMDayanSNancarrowJKWoollattEKremmidiotisGGardnerAVenterDBakerERichardsRI. Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. Hum Mol Genet2000; 9: 1651–63.
9.
KrummelKARobertsLRKawakamiMGloverTWSmithDI. The characterization of the common fragile site FRA16D and its involvement in multiple myeloma translocations. Genomics2000; 69: 37–46.
10.
KrummelKADenisonSRCalhounEPhillipsLASmithDI. The common fragile site FRA16D and its associated gene WWOX are highly conserved in the mouse at Fra8E1. Genes Chromosome Cancer2002; 34: 154–67.
11.
DriouchKPrydzHMoneseRJohansenHLidereauRFrengenE. Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors. Oncogene2002; 21: 1832–40.
12.
EkizogluSMuslumanogluMDalayNBuyruN. Genetic alterations of the WWOX gene in breast cancer. Med Oncol2012; 29: 1529–35.
13.
NunezMILudes-MeyersJAbbaMCKilHAbbeyNWPageRESahinAKlein-SzantoAJAldazCM. Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status. Breast Cancer Res Treat2005; 89: 99–105.
14.
Płuciennik E1KusińskaRPotemskiPKubiakRKordekRBednarekAK. WWOX–the FRA16D cancer gene: expression correlation with breast cancer progression and prognosis. Eur J Surg Oncol2006; 32: 153–7.
15.
WangXChaoLMaGChenLZangYSunJ. The prognostic significance of WWOX expression in patients with breast cancer and its association with the basal-like phenotype. J Cancer Res Clin Oncol2011; 137: 271–8.
16.
YendamuriSKurokiTTrapassoFHenryACDumonKRHuebnerKWilliamsNNKaiserLRCroceCM. WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer. Cancer Res2003; 63: 878–81.
17.
ZhouYLLiYCShouFLiuCQPuYTangH. Reversing effect of exogenous WWOX gene expression on malignant phenotype of primary cultured lung carcinoma cells. Chin Med J (Engl)2010; 123: 615–20.
18.
BeckerSMarkovaBWiewrodtRHoffarthSHähnelPSPleinerSSchmidtLHBreitenbuecherFSchulerM. Functional and clinical characterization of the putative tumor suppressor WWOX in non-small cell lung cancer. J Thorac Oncol2011; 6: 1976–83.
19.
YangJCogdellDYangDHuLLiHZhengHDuXPangYTrentJChenKZhangW. Deletion of the WWOX gene and frequent loss of its protein expression in human osteosarcoma. Cancer Lett2010; 291: 31–8.
20.
ParkSWLudes-MeyersJZimonjicDBDurkinMEPopescuNCAldazCM. Frequent downregulation and loss of WWOX gene expression in human hepatocellular carcinoma. Br J Cancer2004; 91: 753–9.
21.
AqeilanRIKurokiTPekarskyYAlbaghaOTrapassoFBaffaRHuebnerKEdmondsPCroceCM. Loss of WWOX expression in gastric carcinoma. Clin Cancer Res2004; 10: 3053–8.
22.
KurokiTYendamuriSTrapassoFMatsuyamaAAqeilanRIAlderHRattanSCesariRNolliMLWilliamsNNMoriMKanematsuTCroceCM. The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis. Clin Cancer Res2004; 10: 2459–65.
23.
KurokiTTrapassoFShiraishiTAlderHMimoriKMoriMCroceCM. Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. Cancer Res2002; 62: 2258–60.
24.
YangZLanHChenXLiPLiSMoWTangA. Molecular alterations of the WWOX gene in nasopharyngeal carcinoma. Neoplasma2014; 61: 170–6.
25.
Ludes-MeyersJHKilHNuñezMIContiCJParker-ThornburgJBedfordMTAldazCM. WWOX hypomorphic mice display a higher incidence of B-cell lymphomas and develop testicular atrophy. Genes Chromosome Cancer2007; 46: 1129–36.
26.
JennerMWLeonePEWalkerBARossFMJohnsonDCGonzalezDChiecchioLDachs CabanasEDagradaGPNightingaleMProtheroeRKStockleyDElseMDickensNJCrossNCDaviesFEMorganGJ. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood2007; 110: 3291–300.
27.
GardenswartzAAqeilanRI. WW domain-containing oxidoreductase's role in myriad cancers: clinical significance and future implications. Exp Biol Med (Maywood)2014; 239: 253–63.
28.
Del MareSSalahZAqeilanRI. WWOX: its genomics, partners, and functions. J Cell Biochem2009; 108: 737–45.
29.
AqeilanRITrapassoFHussaiSCostineanSMarshallDPekarskyYHaganJPZanesiNKaouMStinGSLianJBCroceCM. Targeted deletion of Wwox reveals a tumor suppressor function. Proc Natl Acad Sci USA2007; 104: 3949–54.
30.
AqeilanRIHaganJPAqeilanHAPichiorriFFongLYCroceCM. Inactivation of the Wwox gene accelerates forestomach tumor progression in vivo. Cancer Res2007; 67: 5606–10.
31.
ZhaoBLiLLeiQGuanKL. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev2010; 24: 862–74.
32.
ZenderLSpectorMSXueWFlemmingPCordon-CardoCSilkeJFanSTLukJMWiglerMHannonGJMuDLucitoRPowersSLoweSW. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell2006; 125: 1253–67.
33.
SteinhardtAAGayyedMFKleinAPDongJMaitraAPanDMontgomeryEAAndersRA. Expression of Yes-associated protein in common solid tumors. Hum Pathol2008; 39: 1582–9.
34.
KimSKJungWHKooJS. Yes-associated protein (YAP) is differentially expressed in tumor and stroma according to the molecular subtype of breast cancer. Int J Clin Exp Pathol2014; 7: 3224–34.
35.
ZhaoBWeiXLiWUdanRSYangQKimJXieJIkenoueTYuJLiLZhengPYeKChinnaiyanAHalderGLaiZCGuanKL. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev2007; 21: 2747–61.
36.
YeungBHoKCYangX. WWP1 E3 ligase targets LATS1 for ubiquitin-mediated degradation in breast cancer cells. PLoS One2013; 8: e61027–e61027.
37.
GaudioEPalamarchukAPalumboTTrapassoFPekarskyYCroceCMAqeilanRI. Physical association with WWOX suppresses c-Jun transcriptional activity. Cancer Res2006; 66: 11585–9.
38.
AqeilanRIDonatiVGaudioENicolosoMSSundvallMKorhonenALundinJIsolaJSudolMJoensuuHCroceCMEleniusK. Association of Wwox with ErbB4 in breast cancer. Cancer Res2007; 67: 9330–6.
39.
AdercaIMoserCDVeerasamyMBani-HaniAHBonilla-GuerreroRAhmedKShireACazanaveSCMontoyaDPMettlerTABurgartLJNagorneyDMThibodeauSNCunninghamJMLaiJPRobertsLR. The JNK inhibitor SP600129 enhances apoptosis of HCC cells induced by the tumor suppressor WWOX. J Hepatol2008; 49: 373–83.
40.
ZhangPJiaRYingLLiuBQianGFanXGeS. WWOX-mediated apoptosis in A549 cells mainly involves the mitochondrial pathway. Mol Med Rep2012; 6: 121–4.
41.
AqeilanRIPekarskyYHerreroJJPalamarchukALetofskyJDruckTTrapassoFHanSYMelinoGHuebnerKCroceCM. Functional association between Wwox tumor suppressor protein and p73, a p53 homolog. Proc Natl Acad Sci USA2004; 101: 4401–6.
42.
GourleyCPaigeAJTaylorKJWardCKuskeBZhangJSunMJanczarSHarrisonDJMuirMSmythJFGabraH. WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3. Cancer Res2009; 69: 4835–42.
43.
AbdeenSKSalahZKhawaledSAqeilanRI. Characterization of WWOX inactivation in murine mammary gland development. J Cell Physiol2013; 228: 1391–6.
44.
Abu-OdehMSalahZHerbelCHofmannTGAqeilanRI. WWOX, the common fragile site FRA16D gene product, regulates ATM activation and the DNA damage response. Proc Natl Acad Sci USA2014. 111:E4617-25.
45.
AqeilanRIHassanMQde BruinAHaganJPVoliniaSPalumboTHussainSLeeSHGaurTSteinGSLianJBCroceCM. The WWOX tumor suppressor is essential for postnatal survival and normal bone metabolism. J Biol Chem2008; 283: 21629–39.
46.
AqeilanRIHaganJPde BruinARawahnehMSalahZGaudioESiddiquiHVoliniaSAlderHLianJBSteinGSCroceCM. Targeted ablation of the WW domain-containing oxidoreductase tumor suppressor leads to impaired steroidogenesis. Endocrinology2009; 150: 1530–5.
47.
LoCPHsuLJLiMYHsuSYChuangJITsaiMSLinSRChangNSChenST. MPP+-induced neuronal death in rats involves tyrosine 33 phosphorylation of WW domain-containing oxidoreductase WOX1. Eur J Neurosci2008; 27: 1634–46.
48.
IatanIChoiHYRuelIReddyMVKilHLeeJOdehMASalahZAbu-RemailehMWeissglas-VolkovDNikkolaECivelekMAwanZCroceCMAqeilanRIPajukantaPAldazCMGenestJ. The WWOX gene modulates high-density lipoprotein and lipid metabolism. Circ Cardiovasc Genet2014; 7: 491–504.
49.
SmeetsDFScheresJMHustinxTW. The most common fragile site in man is 3p14. Hum Genet1986; 72: 215–20.
50.
CohenAJLiFPBergSMarchettoDJTAsiSJacobsSCBrownRS. Hereditary renal-cell carcinoma associated with a chromosomal translocation. New Eng J Med1979; 301: 592–5.
51.
ButlerDCollinsCMabrukMBarry WalshCLeaderMDKayEW. Deletion of the FHIT gene in neoplastic and invasive cervical lesions is related to high-rish HPV infecstion but is independent of histopathological features. J Pathol2000; 192: 502–10.
52.
BoldogFLGemmillRMWilkeCMGloverTWNilssonASChadrasekharappaSCBrownRSLiFPDrabkinHA. Positional cloning of the hereditary renal carcinoma 3;8 chromosome translocation breakpoint. Proc Natl Acad Sci USA1993; 90: 8509–13.
53.
BeckerNAThorlandECDenisonSRPhillipsLASmithDI. Evidence that instability within the FRA3B region extends four megabases. Oncogene2002; 21: 8713–22.
54.
OhtaMInoueHCotticelliMGKasturyKBaffaRPalazzoJSiprashviliZMoriMMcCuePDruckTCroceCMHuebnerK. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell1996; 84: 587–97.
55.
GreenspanDLConnollyDCWuRLeiRYVogelsteinJTKimYTMokJEMuñozNBoschFXShahKChoKR. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Res1997; 57: 4692–8.
56.
FongKMBiesterveldEJVirmaniAWistubaISekidoYBaderSAAhmadianMOngSTRassoolFVZimmermanPVGiacconeGGazdarAFMinnaJD. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res1997; 57: 2256–67.
57.
PandisNBardiGMitelmanFHeimS. Deletion of the short arm of chromosome 3 in breast tumors. Genes Chromosome Cancer1997; 18: 241–5.
58.
KameokaYTagawaHTsuzukiSKarnanSOtaASuguroMSuzukiRYamaguchiMMorishimaYNakamuraSSetoM. Contig array CGH at 3p14.2 points to the FRA3B/FHIT common fragile region as the target gene in diffuse large B-cell lymphoma. Oncogene2004; 23: 9148–54.
59.
IshiiHDumonKRVecchioneATrapassoFMimoriKAlderHMoriMSozziGBaffaRHuebnerKCroceCM. Effect of adenoviral transduction of the fragile histidine triad gene into esophageal cancer cells. Cancer Res2001; 61: 1578–84.
60.
DumonKRIshiiHVecchioneATrapassoFBaldassarreGChakraniFDruckTRosatoEFWilliamsNNBaffaRDuringMJHuebnerKCroceCM. Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. Cancer Res2001; 61: 4827–36.
61.
DumonKRIshiiHFongLYZanesiNFidanzaVManciniRVecchioneABaffaRTrapassoFDuringMJHuebnerKCroceCM. FHIT gene therapy prevents tumor development in Fhit-deficient mice. Proc Natl Acad Sci USA2001; 98: 3346–51.
62.
SaldivarJCMiumaSBeneJHosseiniSAShibataHSunJWheelerLJMathewsCKHuebnerK. Initiation of genome instability and preneoplastic processes through loss of Fhit expression. PLoS Genet2012; 8: e1003077–e1003077.
63.
Hosseini SA1HortonSSaldivarJCMiumaSStampferMRHeeremaNAHuebnerK. Common chromosome fragile sites in human and murine epithelial cells and FHIT/FRA3B loss-induced global genome instability. Genes Chromosome Cancer2013; 52: 1017–29.
64.
SteinCKGloverTWPalmerJLGlissonBS. Direct correlation between FRA3B expression and cigarette smoking. Genes Chromosome Cancer2002; 34: 333–40.
65.
MuranoIKuwanoAKajiiT. Fibroblast-specific common fragile sites induced by aphidicolin. Hum Genet1989; 83: 45–8.
66.
MuranoIKuwanoAKajiiT. Cell type-dependent difference in the distribution and frequency of aphidicolin-induced fragile sites: T and B lymphocytes and bone marrow cells. Hum Genet1989; 84: 71–4.
67.
CaporossiDVernolePNicolettiBTedeschiB. Characteristic chromosomal fragility of human embryonic cells exposed in vitro to aphidicolin. Hum Genet1995; 96: 269–74.
68.
IshiiHVecchioneAFurukawaYSutheesophonKHanSYDruckTKurokiTTrapassoFNishimuraMSaitoYOzawaKCroceCMHuebnerKFurukawaY. Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies. Mol Cancer Res2003; 1: 940–7.
69.
Le TallecBMillotGABlinMEBrisonODutrillauxBDebatisseM. Common fragile site profiling in epithelial and erythroid cells reveals that most recurrent cancer deletions lie in fragile sites hosting large genes. Cell Rep2013; 4: 420–8.
70.
HosseiniSAHortonSSaldivarJCMiumaSStampferMRHeeremaNAHuebnerK. Common chromosome fragile sites in human and murine epithelial cells and FHIT/FRA3B loss-induced global genome instability. Genes Chromosome Cancer2013; 52: 1017–29.
71.
BloomstonMKneileJButterfieldMDillhoffMMuscarellaPEllisonECMelvinWSCroceCMPichiorriFHuebnerKFrankelWL. Coordinate loss of fragile gene expression in pancreatobiliary cancers: correlations among markers and clinical features. Ann Surg Oncol2009; 16: 2331–8.
72.
RoyDSinSHDamaniaBDittmerDP. Tumor suppressor genes FHIT and WWOX are deleted in primary effusion lymphoma (PEL) cell lines. Blood2011; 118: e32–9.
73.
ChenXLiPYangZMoWN. Expression of fragile histidine triad (FHIT) and WW-domain oxidoreductase gene (WWOX) in nasopharyngeal carcinoma. Asian Pac J Cancer Prev2013; 14: 165–71.
74.
De SouzaATHankinsGRWashingtonMKFineRLOrtonTCJirtleRL. Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene1995; 10: 1725–29.
75.
OatesAJSchumakerLMJenkinsSBPearceAADaCostaSAArunBEllisMJ(1998). The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene. Breast Cancer Res Treat1998; 47: 269–81.
76.
ShridharVStaubJHuntleyBClibyWJenkinsRPassHIHartmannLSmithDI. A novel region of deletion on chromosome 6q23.3 spanning less than 500 Kb in high grade invasive epithelial ovarian cancer. Oncogene1999; 18: 3913–8.
77.
KongFMAnscherMSWashingtonMKKillianJKJirtleRL. M6P/IGF2R is mutated in squamous cell carcinoma of the lung. Oncogene2000; 19: 1572–8.
78.
DenisonSRWangFBeckerNASchüleBKockNPhillipsLAKleinCSmithDI. Alterations in the common fragile site gene Parkin in ovarian and other cancers. Oncogene2003; 22: 8370–8.
79.
KitadaTAsakawaSHattoriNMatsumineHYamamuraYMinoshimaSYokochiMMizunoYShimizuN. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature1998; 392: 605–8.
80.
ImaiYSodaMTakahashiR. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J Biol Chem2000; 275: 35661–4.
81.
IwakawaROkayamaHKohnoTSato-OtsuboAOgawaSYokotaJ. Contribution of germline mutations to PARK2 gene inactivation in lung adenocarcinoma. Genes Chromosome Cancer2012; 51: 462–72.
82.
DenisonSRCallahanGBeckerNAPhillipsLASmithDI. Characterization of FRA6E and its potential role in autosomal recessive juvenile Parkinsonism and ovarian cancer. Genes Chromosome Cancer2003; 38(1): 40–52.
83.
TomaMIGrosserMHerrAAustDEMeyeAHoeflingCFuesselSWuttigDWirthMPBarettonGB. Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10 K single nucleotide polymorphism mapping array. Neoplasia2008; 10: 634–42.
84.
LetessierAGarrido-UrbaniSGinestierCFournierGEsterniBMonvilleFAdélaïdeJGeneixJXerriLDubreuilPViensPCharafe-JauffretEJacquemierJBirnbaumDLopezMChaffanetM. Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer. Oncogene2007; 26: 298–307.
85.
PoulogiannisGMcIntyreREDimitriadiMAppsJRWilsonCHIchimuraKLuoFCantleyLCWyllieAHAdamsDJArendsMJ. PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc Natl Acad Sci USA2010; 107: 15145–50.
86.
VeeriahSTaylorBSMengSFangFYilmazEVivancoIJanakiramanMSchultzNHanrahanAJPaoWLadanyiMSanderCHeguyAHollandECPatyPBMischelPSLiauLCloughesyTFMellinghoffIKSolitDBChanTA. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet2010; 42: 77–82.
RozierLEl-AchkarEApiouFDebatisseM. Characterization of a conserved aphidicolin-sensitive common fragile site at human 4q22 and mouse 6C1: possible association with an inherited disease and cancer. Oncogene2004; 23: 6872–80.
89.
SavelyevaLSagulenkoESchmittJGSchwabM. The neurobeachin gene spans the common fragile site FRA13A. Hum Genet2006; 118: 551–8.
90.
McAvoySGanapathirajuSCDucharme-SmithALPritchettJRKosariFPerezDSZhuYJamesCDSmithDI. Non-random inactivation of large common fragile site genes in different cancers. Cytogenet Genome Res2007; 118: 260–69.
91.
DaiJRamPTYuanLSpriggsLLHillSM. Transcriptional repression of RORalpha activity in human breast cancer cells by melatonin. Mol Cell Endocrinol2001; 176: 111–20.
92.
RamPTDaiJYuanLDongCKieferTLLaiLHillSM. Involvement of the mt1 melatonin receptor in human breast cancer. Cancer Lett2002; 179: 141–50.
93.
ZhuYMcAvoySKuhnRSmithDI. RORA, a large common fragile site gene, is involved in cellular stress response. Oncogene2006; 25: 2901–8.
94.
McAvoySGanapathirajuSPerezDSJamesCDSmithDI. DMD and IL1RAPL1: two large adjacent genes localized within a common fragile site (FRAXC) have reduced expression in cultured brain tumors. Cytogenet Genome Res2007; 119: 196–203.
95.
HosurVKavirayaniARieflerJCarneyLMLyonsBGottBCoxGAShultzLD. Dystrophin and dysferlin double mutant mice: a novel model for rhabdomyosarcoma. Cancer Genet2012; 205: 232–41.
96.
O'NealJGaoFHassanAMonahanRBarriosSKilimannMWLeeIChngWJVijRTomassonMH. Neurobeachin (NBEA) is a target of recurrent interstitial deletions at 13q13 in patients with MGUS and multiple myeloma. Exp Hematol2009; 37: 234–44.
97.
CowinPAGeorgeJFeredaySLoehrerEVan LooPCullinaneC. Etemadmoghadam D, Ftouni S, Galletta L, Anglesio MS, Hendley J, Bowes L, Sheppard KE, Christie EL, Pearson RB, Harnett PR, Heinzelmann-Schwarz V, Friedlander M, McNally O, Quinn M, Campbell P, deFazio A, Bowtell DD. Australian Ovarian Cancer Study. LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. Cancer Res2012; 72: 4060–73.
98.
NagoshiHTakiTHanamuraINittaMOtsukiTNishidaKOkudaKSakamotoNKobayashiSYamamoto-SugitaniMTsutsumiYKobayashiTMatsumotoYHoriikeSKurodaJTaniwakiM. Frequent PVT1 rearrangement and novel chimeric genes PVT1-NBEA and PVT1-WWOX occur in multiple myeloma with 8q24 abnormality. Cancer Res2012; 72: 4954–62.
GaoGKasperbauerJLTombersNMWangVMayerKSmithDI. A selected group of large common fragile site genes have decreased expression in oropharyngeal squamous cell carcinomas. Genes Chromosome Cancer2014; 53: 392–401.
101.
WatanabeAHippoYTaniguchiHIwanariHYashiroMHirakawaKKodamaTAburataniH. An opposing view on WWOX protein function as a tumor suppressor. Cancer Res2003; 63: 8629–33.
102.
SozziGSardLDe GregorioLMarchettiAMussoKButtittaFTornielliSPellegriniSVeroneseMLManentiGIncarboneMChellaAAngelettiCAPastorinoUHuebnerKBevilaquaGPilottiSCroceCMPierottiMA. Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res1997; 57: 2121–3.
103.
SteinCKGloverTWPalmerJLGlissonBS. Direct correlation between FRA3B expression and cigarette smoking. Genes Chromosome Cancer2002; 34: 333–40.
104.
HolschneiderCHBaldwinRLTumberKAoyamaCKarlanBY. The fragile histidine triad gene: a molecular link between cigarette smoking and cervical cancer. Clin Cancer Res2005; 11: 5756–63.
105.
ThavathiruELudes-MeyersJHMacLeodMCAldazCM. Expression of common chromosomal fragile site genes, WWOX/FRA16D and FHIT/FRA3B is downregulated by exposure to environmental carcinogens, UV, and BPDE but not by IR. Mol Carcinog2005; 44: 174–82.
106.
SbranaIVeroniFNieriMPulitiABaraleR. Chromosomal fragile sites FRA3B and FRA16D show correlated expression and association with failure of apoptosis in lymphocytes from patients with thyroid cancer. Genes Chromosome Cancer2006; 45: 429–36.
107.
Helmrich A1BallarinoMToraL. Collisions between replication and transcription complexes cause common fragile site instability at the longest human genes. Mol Cell201; 44: 966–77.
